Toward effective targeted therapies for Acute Myeloid Leukaemia (AML) [ 2017 - ]

Research Grant

Researchers: A/Pr Andrew Wei (Principal investigator) ,  A/Pr Marco Herold ,  Prof Stefan Bohlander

Brief description Standard chemotherapy for acute myeloid leukaemia (AML) is highly toxic, and has not changed in over 40 years. We will conduct a world-first clinical trial incorporating ABT-199 (Venetoclax) to target BCL2 into the standard-of-care treatment for AML. A second initiative will explore the potential for small molecule inhibitors to simultaneously target both BCL2 and its related partner MCL1, to create a “chemotherapy-free” regimen for AML. These studies promise to herald a new era in AML therapy.

Funding Amount $551,345.00

Funding Scheme Project Grants

Notes Standard Project Grant